BioCentury | Sep 15, 2008
Strategy

More pep in their step

...product to market. Since June, the company has completed a private placement, agreed to aquire Neosil Inc....
...New Enterprise Associates; Asia Union Investments; and Orbis Funds Management. And in June it acquired Neosil...
...listing on NASDAQ, but pulled its proposed IPO in June just as it announced the Neosil...
BioCentury | Aug 25, 2008
Company News

Peplin management update

...Emeryville, Calif. Business: Dermatology, Cancer Hired: Eugene Bauer as president and CMO, formerly CEO of Neosil Inc....
BioCentury | Aug 20, 2008
Financial News

Peplin raises US$24 million

...The company also hired Eugene Bauer as president and CMO. Previously, Bauer was CEO of Neosil...
BioCentury | Jun 16, 2008
Company News

Neosil, Peplin deal

...US$6.7 million in stock, which is the amount of net cash Neosil held at signing. Neosil...
...held at signing. Neosil shareholders will own about 7.3% of Peplin. Peplin plans to use Neosil’s...
...is in Phase II testing for BCC. Peplin does not expect to begin development of Neosil’s...
BioCentury | Jun 16, 2008
Finance

Ebb & Flow

...US$6.7 million in stock, which is the amount of net cash Neosil held at signing. Neosil...
...held at signing. Neosil shareholders will own about 7.3% of Peplin. Peplin plans to use Neosil's...
BioCentury | Jun 12, 2008
Financial News

Peplin pulls IPO

...up to US$75 million on NASDAQ. Also on Tuesday, Peplin agreed to acquire dermatology company Neosil...
...at signing. Neosil shareholders will own about 7.3% of Peplin . Peplin plans to use Neosil's...
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
BioCentury | Jun 18, 2007
Company News

WaferGen Biosystems Inc. scientific advisory board update

...WaferGen Biosystems Inc. (WGBS), Fremont, Calif. Business: Supply/Service Appointed: Eugene Bauer, CEO of Neosil Inc., as chairman WIR...
BioCentury | Jan 8, 2007
Clinical News

NEOSH101: Phase IIa data

...or placebo over two 14-day treatment periods that were separated by a 1-month treatment-free interval. Neosil Inc....
BioCentury | May 2, 2005
Finance

MPM's portfolio

...E 10/28/03 $24.9 Luke Evnin Mindset Neurology Israel ND 12/19/01 $15.0 Ansbert Gadicke, Edward Mascioli Neosil...
Items per page:
1 - 10 of 18
BioCentury | Sep 15, 2008
Strategy

More pep in their step

...product to market. Since June, the company has completed a private placement, agreed to aquire Neosil Inc....
...New Enterprise Associates; Asia Union Investments; and Orbis Funds Management. And in June it acquired Neosil...
...listing on NASDAQ, but pulled its proposed IPO in June just as it announced the Neosil...
BioCentury | Aug 25, 2008
Company News

Peplin management update

...Emeryville, Calif. Business: Dermatology, Cancer Hired: Eugene Bauer as president and CMO, formerly CEO of Neosil Inc....
BioCentury | Aug 20, 2008
Financial News

Peplin raises US$24 million

...The company also hired Eugene Bauer as president and CMO. Previously, Bauer was CEO of Neosil...
BioCentury | Jun 16, 2008
Company News

Neosil, Peplin deal

...US$6.7 million in stock, which is the amount of net cash Neosil held at signing. Neosil...
...held at signing. Neosil shareholders will own about 7.3% of Peplin. Peplin plans to use Neosil’s...
...is in Phase II testing for BCC. Peplin does not expect to begin development of Neosil’s...
BioCentury | Jun 16, 2008
Finance

Ebb & Flow

...US$6.7 million in stock, which is the amount of net cash Neosil held at signing. Neosil...
...held at signing. Neosil shareholders will own about 7.3% of Peplin. Peplin plans to use Neosil's...
BioCentury | Jun 12, 2008
Financial News

Peplin pulls IPO

...up to US$75 million on NASDAQ. Also on Tuesday, Peplin agreed to acquire dermatology company Neosil...
...at signing. Neosil shareholders will own about 7.3% of Peplin . Peplin plans to use Neosil's...
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
BioCentury | Jun 18, 2007
Company News

WaferGen Biosystems Inc. scientific advisory board update

...WaferGen Biosystems Inc. (WGBS), Fremont, Calif. Business: Supply/Service Appointed: Eugene Bauer, CEO of Neosil Inc., as chairman WIR...
BioCentury | Jan 8, 2007
Clinical News

NEOSH101: Phase IIa data

...or placebo over two 14-day treatment periods that were separated by a 1-month treatment-free interval. Neosil Inc....
BioCentury | May 2, 2005
Finance

MPM's portfolio

...E 10/28/03 $24.9 Luke Evnin Mindset Neurology Israel ND 12/19/01 $15.0 Ansbert Gadicke, Edward Mascioli Neosil...
Items per page:
1 - 10 of 18